赛马鲁肽
医学
杜拉鲁肽
内科学
兴奋剂
胰高血糖素样肽1受体
艾塞那肽
糖尿病
2型糖尿病
受体
利拉鲁肽
内分泌学
作者
Mansoor Husain,Andreas L. Birkenfeld,Morten Donsmark,Kathleen Dungan,Freddy G. Eliaschewitz,Denise Reis Franco,Ole K. Jeppesen,Ildiko Lingvay,Ofri Mosenzon,Sue D. Pedersen,Cees J. Tack,Mette S. Thomsen,Tina Vilsbøll,Mark Warren,Stephen C. Bain
标识
DOI：10.1056/nejmoa1901118
摘要
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.
科研通智能强力驱动
Strongly Powered by AbleSci AI
请叫我风吹麦浪
劲秉
科研小民工
nozero
彭于彦祖
爱静静
迷人秋烟
bc
cdercder
Singularity
昏睡的蟠桃
zho
默默地读文献
maox1aoxin
QOP
sssss
迟大猫
持卿
pluto
子车茗
皖公网安备34019202002308
